Hypertension
Conditions
Interventions
Randomided after 4 weeks administration of 20mg of olmesartan. 16mg of azelnizipine is administered for 8 weeks after randomization
Randomided after 4 weeks administration of 20mg of olmesartan. 5mg o
Sponsors
Advanced Medicine Study Group in Kyushu Island
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with type2 diabetes 2. Patients with hypertension 3. Outpatient
Exclusion criteria
Exclusion criteria: 1. Patients using insulin 2. Patients with secondary hypertension 3. Patients on hemodialysis 4. Pregnant women or those who plan pregnancy 5. Patients with history of hypersensitivity to olmesartan, azelnizipine, amlodipine 6. Patients with severe liver injury 7. Patients with severe renal failure (serum CRE>=3.0mg/dl) 8. Other patients judged unsuitable for the study by investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| fasting plasma glucose, insulin HbA1c T-Chol, HDL-C, LDL-C, TG hs-CRP, HM-adiponectine nitrotyrosine, urinary 8-isoprostan | — |
Secondary
| Measure | Time frame |
|---|---|
| home or clinic blood pressure | — |
Countries
Japan
Contacts
Public ContactMasanari Mizuta
University of Miyazaki Faculty of Medicine Division of Endocrinology and metabolism, Department of Medicine
Outcome results
None listed